| Eikon Therapeutics, Inc. |
10%+ Owner |
Common Stock |
4,312,139 |
|
|
06 Feb 2026 |
By The Column Group IV, LP |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Common Stock |
1,319,164 |
|
|
06 Feb 2026 |
By The Column Group Opportunity III, LP |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Common Stock |
148,840 |
|
|
06 Feb 2026 |
By The Column Group IV-A, LP |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Common Stock |
3,352 |
|
|
04 Feb 2026 |
Indirect |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series A-1 Preferred Stock |
0 |
|
|
06 Feb 2026 |
By The Column Group IV-A, LP |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series A-1 Preferred Stock |
0 |
|
|
06 Feb 2026 |
By The Column Group IV, LP |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series A Preferred Stock |
0 |
|
|
06 Feb 2026 |
By The Column Group IV-A, LP |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series A Preferred Stock |
0 |
|
|
06 Feb 2026 |
By The Column Group IV, LP |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series C-1 Preferred Stock |
0 |
|
|
06 Feb 2026 |
By The Column Group IV-A, LP |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series C-1 Preferred Stock |
0 |
|
|
06 Feb 2026 |
By The Column Group IV, LP |
| Eikon Therapeutics, Inc. |
10%+ Owner |
Series D Preferred Stock |
0 |
|
|
06 Feb 2026 |
By The Column Group Opportunity III, LP |